Dr. Ankur Nandan Varshney
Consultant
14 years of experienceMedical Oncologists
MBBS, MD, DM
Medanta - The Medicity Medical Centre, Gurgaon
Book an AppointmentAbout Dr. Ankur Nandan Varshney
Dr. Ankur Nandan Varshney is an accomplished medical oncologist with an impressive 14 years of professional experience. He focuses on areas such as cancer immunotherapy, breast cancer, GI malignancies, lung cancer, urogenital cancers, multiple myeloma, lymphoma, leukemia, pediatric solid tumors, stem cell transplantation, and pain and palliative care. His educational qualifications include an MBBS from Banaras Hindu Univ. 2010, an MD in General Medicine from Banaras Hindu Univ. 2014, and a DM in Medical Oncology from All India Inst. of Medical Sciences (AIIMS), New Delhi, 2021 Dr. Varshney has presented numerous publications at international conferences, showcasing his expertise and dedication to advancing the field of medical oncology. He is dedicated to delivering exceptional patient care while actively contributing to the progress of medical oncology.Education
MBBS, Banaras Hindu Univ., 2010 MD (General Medicine), Banaras Hindu Univ., 2014 DM (Medical Oncology), All India Inst. of Medical Sciences (AIIMS), New Delhi, 2021Past Experience
All India Inst. of Medical Sciences (AIIMS), New Delhi Safdarjung Hosp. New Delhi National Cancer Inst. Jhajjar HaryanaAwards
Won Deeptanshu Vedanta Gupta Gold Medal Won “Best Poster Prize and Gold Medal” at UP-APICON 2013 Selected and attended ESMO Lung preceptorship in November 2020 Won ESH scholarship accolade for the 22nd John Goldman Conference 2020 Won a Young Investigator travel grant for the SOHO Conference 2021. Selected for Young Investigator accolade for SOHO conference 2022
Paper Published
CML-362 Study to Evaluate the Effect of Fatty Meals on Nilotinib Drug Levels in Patients of Chronic Myeloid Leukemia–Chronic Phase and Correlate Its In-Vivo Activity With STAT1, STAT5, and AKT 1 Levels 515P Prognostic significance of elevated serum tumor markers (STM) after the first cycle of chemotherapy in patients with intermediate and poor risk non-seminomatous testicular germ cell tumors (NSGCT) Prognostic significance of raised serum tumor markers (STM) after two cycles of chemotherapy in men with intermediate- and poor-risk non-seminomatous testicular germ cell tumors (NSGCT) treated at a single-center in India. Comparison of quality of life (QoL) in survivors of testicular nonseminomatous germ cell tumor (NSGCT) with age-matched controls using EORTC QLQ-C30 questionnaire. CML-268: Study to Evaluate the Effect of Fatty Meals on Nilotinib Drug Levels in Patients with CML-CP Poster: CML-268: Study to Evaluate the Effect of Fatty Meals on Nilotinib Drug Levels in Patients with CML-CP Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient 471PChemotherapy in advanced thymic malignancies Primary Plasma Cell Leukemia: a retrospective series from a tertiary care center in India Preemptive plerixafor-based mobilization strategy in multiple myeloma patients for autologous stem cell transplantation Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient Preemptive plerixafor-based mobilization strategy in multiple myeloma patients for autologous stem cell transplantation
Area of Expertise
- Chemotherapy
- Endometrial Biopsy
- Fine Needle Aspiration
- Hormone Therapy
- Immunotherapy
- Microsurgical Tumor Removal